Effects of lopinavir-ritonavir combined therapy during the rat pregnancy morphological and biochemical aspects

被引:8
作者
Cunha, A. M.
Hagemann, C. C. F.
Simoes, R. S.
Oliveira-Filho, R. M.
Simoes, M. J.
Soares, J. M., Jr. [1 ]
Maciel, G. A. R.
Oliveira, F. H. M.
Amed, A. A.
Kulay, L., Jr.
机构
[1] Univ Fed Sao Paulo, Dept Obstet, Sch Med, Sao Paulo, Brazil
[2] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Sao Paulo, Brazil
[3] Univ Fed Sao Paulo, Dept Morphol, Sch Med, Sao Paulo, Brazil
[4] Univ Fed Sao Paulo, Dept Gynecol, Sch Med, Sao Paulo, Brazil
[5] Santa Casa Misericordia Sao Paulo, Sch Med, Sao Paulo, Brazil
来源
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY | 2007年 / 133卷 / 01期
关键词
lopinavir; ritonavir; toxicology; pregnancy; rat; HIV PROTEASE INHIBITORS; COMBINATION; TRANSMISSION; PLASMA; WOMEN;
D O I
10.1016/j.ejogrb.2006.08.004
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate the biochemical and morphological effects in rats subjected to three different dose associations of the protease inhibitors lopinavir and ritonavir administered throughout the entire period of pregnancy. Study design: The animals were treated throughout pregnancy with daily oral doses of lopinavir + ritonavir starting at the day one of pregnancy, and were divided into four groups: E1, 13.3 + 3.3 mg/kg; E2, 39.9 + 9.9 mg/kg; E3, 119.7 + 29.9 mg/kg and C, control (drug vehicle, propyleneglycol). The animals were then sacrificed and maternal blood and fetal and maternal organ samples were taken for morphological and biochemical analysis. Results: No major changes were identified in the group treated with the lowest dose as compared with the control. In the group E2, we found hepatocytes with signs of atrophy, eosinophilic cytoplasm, picnotic nuclei and vasodilatation. The proximal convoluted tubules of maternal kidneys showed eosinophilic areas and hyperchromatic nuclei, as well as signs of vasodilation. In the group treated with the highest dose (group E3), in the maternal kidneys and livers, the morphological changes were similar to those found in E2, although more prominent. Regarding the fetal organs, the single abnormality observed was some liver vasodilation in the group E3 (highest dose). The treatment with lopinavir + ritonavir caused discrete, yet significant, alterations of aspartate aminotransferase activity, blood urea nitrogen and creatinine plasma levels. Conclusions: Our results showed that the administration of a combination of lopinavir plus ritonavir to pregnant rats can cause morphological as well as functional changes in maternal and fetal liver and kidneys and, in higher than therapeutic doses, might be toxic to those animals. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:60 / 63
页数:4
相关论文
共 23 条
  • [1] A role for P-glycoprotein in environmental toxicology
    Abu-Qare, AW
    Elmasry, E
    Abou-Donia, MB
    [J]. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS, 2003, 6 (03): : 279 - 288
  • [2] Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers
    Alsenz, J
    Steffen, H
    Alex, R
    [J]. PHARMACEUTICAL RESEARCH, 1998, 15 (03) : 423 - 428
  • [3] SERUM CREATININE DETERMINATION WITHOUT PROTEIN PRECIPITATION
    BARTELS, H
    BOHMER, M
    HEIERLI, C
    [J]. CLINICA CHIMICA ACTA, 1972, 37 (NMAR) : 193 - &
  • [4] Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire
    Bertolli, J
    StLouis, ME
    Simonds, RJ
    Nieburg, P
    Kamenga, M
    Brown, C
    Tarande, M
    Quinn, T
    Ou, CY
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (04) : 722 - 726
  • [5] Carvalho A M, 2004, Clin Exp Obstet Gynecol, V31, P229
  • [6] Colombo S, 2006, ANTIVIR THER, V11, P53
  • [7] Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009
  • [8] CORGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337
  • [9] EHRST A, 1991, LANCET, V338, P203
  • [10] Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens
    Gutiérrez, F
    Padilla, S
    Navarro, A
    Masiá, M
    Hernández, I
    Ramos, J
    Esteban, A
    Martin-Hidalgo, A
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (05) : 594 - 600